Mostrar el registro sencillo del ítem

dc.contributor.authorPires, Filipa Velez
dc.contributor.authorArcos Martínez, Julia 
dc.contributor.authorCabral, A. Cristina Dias
dc.contributor.authorVidal, Juan C. .
dc.contributor.authorCastillo, Juan R. .
dc.date.accessioned2018-05-16T08:30:27Z
dc.date.issued2018-07
dc.identifier.issn0731-7085
dc.identifier.urihttp://hdl.handle.net/10259/4787
dc.description.abstractHuman cytomegalovirus (HCMV) is a herpes virus that can cause severe infections. Still, the available methods for its diagnostic have the main disadvantage of requiring long time to be performed. In this work, a simple magnetic particle-based enzyme immunoassay (mpEIA) for the quantification of glycoprotein B of Human cytomegalovirus (gB-HCMV) in urine samples is proposed. The immunosensor scheme is based on the analyte protein gB-HCMV sandwiched between a primary monoclonal antibody, (MBs-PrG-mAb1), and a secondary anti-gB-HCMV antibody labelled with Horseradish peroxidase (Ab2-HRP) to allow spectrophotometric detection. The mpEIA analytical performance was tested in urine samples, showing a linear dependence between gB-HCMV concentration and the absorbance signal at 450 nm in a range of concentrations from 90 to 700 pg mL−1. The calculated detection limits for gB-HCMV were 90 ± 2 pg mL−1 and the RSD was about 6.7% in urine samples. The immunosensor showed good selectivity against other viruses from Herpesviridae family, namely varicella zoster and Epstein Barr viruses. The recoveries of spiked human urine samples at 0.30–0.50 ng mL−1 concentration levels of gB-HCMV ranged between 91 to 105%. The proposed mpEIA method was validated following the guidelines of the European Medicines Agency (EMEA-2014), and allows rapid, successful and easy quantification of gB-HCMV in urine samples.en
dc.description.sponsorshipFEDER funds through the POCI – COMPETE 2020 – Operational Program Competitiveness and Internationalization in Axis I – Strengthening research, technological development and innovation (Project No. POCI-01-0145-FEDRER-007491), Portuguese Funds by FCT - Foundation for Science and Technology (Project UID/Multi/00709/2013) and Spanish Ministry of Science and Innovation (MICINN), Ministry of Economy and Competitiveness (MINECO) and the European Regional Development Fund (FEDER) (TEC20013-40561-P and MUSSEL RTC-2015-4077-2en
dc.format.mimetypeapplication/pdf
dc.language.isoenges
dc.publisherElsevieren
dc.relation.ispartofJournal of Pharmaceutical and Biomedical Analysis. 2018, V. 156, p. 372-378en
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectMagnetic beadsen
dc.subjectImmunoassayen
dc.subjectmpEIAen
dc.subjectHuman cytomegalovirusen
dc.subjectGlycoprotein Ben
dc.subject.otherChemistry, Analyticen
dc.subject.otherQuímica analíticaes
dc.titleA rapid magnetic particle-based enzyme immunoassay for human cytomegalovirus glycoprotein B quantificationen
dc.typeinfo:eu-repo/semantics/article
dc.date.embargo2020-07
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.relation.publisherversionhttps://doi.org/10.1016/j.jpba.2018.04.019
dc.identifier.doi10.1016/j.jpba.2018.04.019
dc.relation.projectIDinfo:eu-repo/grantAgreement/UE/POCI-01-0145-FEDRER-007491
dc.relation.projectIDinfo:eu-repo/grantAgreement/FCT-Foundation for Science and Technology/UID/Multi/00709/2013
dc.relation.projectIDinfo:eu-repo/grantAgreement/MICINN/TEC20013-40561-P
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO/RTC-2015-4077-2
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersionen


Ficheros en este ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem